菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi Biologics Selected for S&P Global Sustainability Yearbook 2024
Apr. 15, 2024
WuXi Biologics Selected for S&P Global Sustainability Yearbook 2024

SHANGHAI, April 15, 2024 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been selected for the S&P Global Sustainability Yearbook 2024 (“Yearbook”) for its strong sustainability performance in 2023.

 

 

The Yearbook aims to distinguish individual companies within a range of industries that have demonstrated strong corporate sustainability, based on the S&P’s Corporate Sustainability Assessment (CSA). Over 9,400 companies were assessed in the 2023 CSA, and 759 top-performing companies were selected for the 2024 Yearbook. WuXi Biologics received a Top 1% S&P Global CSA Score.

 

 

 

In 2023, WuXi Biologics realized a 29% greenhouse gas emission intensity reduction from the base year 2020. In addition, the company achieved water consumption intensity reduction target ahead of schedule, and upgraded the target from 18% to 30% intensity reduction by 2025 from the base year 2019. Actively promoting Diversity, Equity and Inclusion (DEI), WuXi Biologics has 47% female employees in managerial positions and 53% STEM positions are held by female employees.

 

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the Environmental, Social, and Governance (ESG) Committee, commented, “We are very pleased to be named in the S&P Global Sustainability Yearbook 2024, which follows our inclusion into the Dow Jones Sustainability World Index and the Dow Jones Sustainability Emerging Markets Index last year. These achievements are a reflection of our deep commitment to continually enhancing our ESG capabilities and further driving the company’s sustainable growth for the common good of the global community.”

 

WuXi Biologics regards sustainability as the cornerstone of its business. In the past year, it has achieved a number of notable ESG milestones. In June, the company signed the Science Based Targets initiative (SBTi) commitment letter, a new pledge in support of the goal to achieve net-zero greenhouse gas emissions by 2050. In September, the company also became a participant to the United Nations Global Compact, further demonstrating its sustainability commitment. In November, WuXi Biologics received an AAA rating from MSCI ESG Ratings and an EcoVadis Sustainability Rating’s Platinum Medal, the highest recognition granted to the companies being evaluated.